American Journal of Obstetrics & Gynecology
Volume 194, Issue 2 , Pages 397-401, February 2006

Sonographic screening for trisomy 13 at 11 to 13+6 weeks of gestation

  • Aris T. Papageorghiou, MD

      Affiliations

    • Harris Birthright Research Centre for Fetal Medicine, King's College Hospital Medical School, London, United Kingdom
  • ,
  • Kyriaki Avgidou, MD

      Affiliations

    • Harris Birthright Research Centre for Fetal Medicine, King's College Hospital Medical School, London, United Kingdom
  • ,
  • Kevin Spencer, DSc

      Affiliations

    • Prenatal Screening Unit, Department of Clinical Biochemistry, Harold Wood Hospital, Gubbins Lane, Essex, United Kingdom
  • ,
  • Barry Nix, PhD

      Affiliations

    • Department of Epidemiology, Statistics and Public Health, Cardiff University, Cardiff, United Kingdom
  • ,
  • Kypros H. Nicolaides, MD

      Affiliations

    • Harris Birthright Research Centre for Fetal Medicine, King's College Hospital Medical School, London, United Kingdom
    • Corresponding Author InformationReprint requests: K. H. Nicolaides, MD, Harris Birthright Research Centre for Fetal Medicine, King's College Hospital Medical School, Denmark Hill, London SE5 8RX.

Received 12 April 2005; received in revised form 6 May 2005; accepted 4 August 2005.

Objective

The purpose of this study was to examine the sonographic features of trisomy 13 at 11 to 13+6 weeks of gestation.

Study design

This was a retrospective study that examined the features of trisomy 13 at the ultrasound scan at 11 to 13+6 weeks of gestation, which in our center is performed for the measurement of crown-rump length, nuchal translucency thickness, and fetal heart rate and the examination for major defects.

Results

In the 181 fetuses with trisomy 13, there were holoprosencephaly, exomphalos, and/or megacystis in 92 fetuses (50.2%), fetal heart rate above the 95th percentile in 129 fetuses (71.3%), and nuchal translucency above the 95th percentile in 141 fetuses (77.9%). There was no significant association between nuchal translucency and fetal heart rate, and it was estimated that inclusion of fetal heart rate in nuchal translucency screening can improve the detection rate of trisomy 13 by approximately 5%.

Conclusion

At the 11 to 13+6–week scan, the measurement of fetal nuchal translucency and fetal heart rate and fetal examination for holoprosencephaly, exomphalos, and megacystis can identify >90% of fetuses with trisomy 13.

Key words: First-trimester screening, Nuchal translucency, Fetal heart rate, Trisomy 13

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 30.00 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

 Supported by the Fetal Medicine Foundation (Registered Charity 1037116).

PII: S0002-9378(05)01250-0

doi:10.1016/j.ajog.2005.08.010

American Journal of Obstetrics & Gynecology
Volume 194, Issue 2 , Pages 397-401, February 2006